349 related articles for article (PubMed ID: 1586980)
1. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
Schott B; Robert J
Biochem Pharmacol; 1989 Nov; 38(22):4069-74. PubMed ID: 2597184
[TBL] [Abstract][Full Text] [Related]
3. DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.
Ferrazzi E; Woynarowski JM; Arakali A; Brenner DE; Beerman TA
Cancer Commun; 1991 Jun; 3(6):173-80. PubMed ID: 2049226
[TBL] [Abstract][Full Text] [Related]
4. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Limonta M; Biondi A; Giudici G; Specchia G; Catapano C; Masera G; Barbui T; D'Incalci M
Cancer Chemother Pharmacol; 1990; 26(5):340-2. PubMed ID: 2208574
[TBL] [Abstract][Full Text] [Related]
7. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
10. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
11. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids.
Orlandi P; Barbara C; Bocci G; Fioravanti A; Di Paolo A; Del Tacca M; Danesi R
J Chemother; 2005 Dec; 17(6):663-7. PubMed ID: 16433198
[TBL] [Abstract][Full Text] [Related]
14. Influence of idarubicinol on the antileukemic effect of idarubicin.
Fukushima T; Kawai Y; Urasaki Y; Yoshida A; Ueda T; Nakamura T
Leuk Res; 1994 Dec; 18(12):943-7. PubMed ID: 7996875
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
16. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Kuffel MJ; Ames MM
Cancer Chemother Pharmacol; 1995; 36(3):223-6. PubMed ID: 7781142
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin: an anthracycline antineoplastic agent.
Cersosimo RJ
Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.
Bajraktari-Sylejmani G; Oster JS; Burhenne J; Haefeli WE; Sauter M; Weiss J
Arch Toxicol; 2024 Mar; 98(3):807-820. PubMed ID: 38175295
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]